Big Molecule Watch

AUGUST 6, 2024

The products were deemed highly similar to Janssen’s STELARA (ustekinumab), which was authorized in the EU on January 15, 2009. The post EU Committee Recommends Approval of 6 New Biosimilars in July 2024 Meeting appeared first on Big Molecule Watch.

Biosimilars 59

Biosimilars Diabetes 59

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

PharmaShots

JUNE 7, 2023

Our team at PharmaShots has summarized 16 key events of the biosimilar space of May 2023 1. Sandoz Reports Real World Study Results of GP2013 (biosimilar, rituximab) for the Treatment of Rheumatoid Arthritis Date- May 08, 2023 Product: GP2013 (biosimilar, rituximab) The study incl. 84% vs 64%) & 2yr. (60%

Biosimilars 40

Biosimilars Packaging Diabetes Pharmaceutical Companies 40

PharmaShots

MARCH 29, 2023

Some companies accept the offered period and open doors to biological drugs or biosimilars. Indication: Type 2 Diabetes Mellitus Victoza is a non-insulin, anti-diabetic medicine used for the treatment of type 2 diabetes and to reduce the risk of cardiovascular events associated with the disease.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunity 49

PharmaShots

APRIL 13, 2023

2009 was a challenging year for multinational companies due to the recession and currency fluctuations Johnson & Johnson's performance graph declined by 2.9% Despite a challenging year, Johnson & Johnson acquired Cougar and Elan Pfizer's 2009 performance was significant as compared to 2008 with the addition of Wyeth.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

DECEMBER 2, 2020

Others rapidly followed, including Glucotrol, aimed at diabetics, and Procardia, an anti-hypertensive. Since the turn of the millennium, Pfizer has embarked on a series of mega-mergers, gobbling up Warner-Lambert in 2000, Pharmacia and Upjohn in 2002, Wyeth in 2009, and Medivation in 2016.

Compounding 128

Compounding Vaccines Biosimilars Diabetes 128

pharmaphorum

FEBRUARY 26, 2021

During this tenure, J&J entered into the areas of vision care, mechanical wound closure and diabetes management. The litigation was settled in 2009, when Boston Scientific agreed to pay $716 million in September and an additional $1.73 Acquisitions post-Janssen. Between 1976 and 1989, James E. Burke was chairman and CEO of J&J.

Vaccines 126

Vaccines Biosimilars Labelling Communication 126